

UNITED STATES PATENT APPLICATION

OF

MARC ALIZON
LUC MONTAGNIER
DENISE GUETARD
FRANCOIS CLAVEL
PIERRE SONIGO
AND
MIREILLE GUYADER

FOR

CLONED DNA SEQUENCES RELATED TO THE ENTIRE GENOMIC
RNA OF HUMAN IMMUNODEFICIENCY VIRUS II (HIV-2),
POLYPEPTIDES ENCODED BY THESE DNA SEQUENCES
AND USE OF THESE DNA CLONES AND POLYPEPTIDES
IN DIAGNOSTIC KITS

Background of the Invention

This application is a continuation-in-part of U.S. Patent Application _____ of Alizon et al. for "Cloned DNA Sequences Related to the Entire Genomic RNA of Human Immunodeficiency Virus II (HIV-2), Polypeptides Encoded by these DNA Sequences and Use of these DNA Clones and Polypeptides in Diagnostic Kits," filed January 16, 1987, which is a continuation-in-part of U.S. Patent Application Serial No. 931,866 filed November 21, 1986, which is a continuation-in-part application of U.S. Patent Application Serial No. 916,080 of Montagnier et al. for "Cloned DNA Sequences Related to the Genomic RNA of the Human Immunodeficiency Virus II (HIV-2), Polypeptides Encoded by these DNA Sequences and Use of these DNA Clones and Polypeptides in Diagnostic Kits," filed October 6, 1986 and U.S. Patent Application Serial No. 835,228 of Montagnier et al. for "New Retrovirus Capable of Causing AIDS, Antigens Obtained from this Retrovirus and Corresponding Antibodies and their Application for Diagnostic Purposes," filed March 3, 1986. The disclosures of each of these predecessor applications are expressly incorporated herein by reference.

The invention relates to cloned DNA sequences analogous to the genomic RNA of a virus known as Lymphadenopathy-Associated Virus II ("LAV-II"), a process for the preparation of these cloned DNA sequences, and their use as probes in diagnostic kits. In one embodiment, the invention relates to a cloned DNA sequence analogous to the entire genomic RNA of HIV-2 and its use as a

probe. The invention also relates to polypeptides with amino acid sequences encoded by these cloned DNA sequences and the use of these polypeptides in diagnostic kits.

According to recently adopted nomenclature, as reported in Nature, May 1986, a substantially-identical group of retroviruses which has been identified as one causative agent of AIDS are now referred to as Human Immunodeficiency Viruses I (HIV-1). This previously-described group of retroviruses includes Lymphadenopathy-Associated Virus I (LAV-I), Human T-cell Lymphotropic Virus-III (HTLV-III), and AIDS-Related Virus (ARV).

Lymphadenopathy-Associated Virus II has been described in United States Application Serial No. 835,228, which was filed March 3, 1986, and is specifically incorporated herein by reference. Because LAV-II is a second, distinct causative agent of AIDS, LAV-II properly is classifiable as a Human Immunodeficiency Virus II (HIV-2). Therefore, "LAV-II" as used hereinafter describes a particular genus of HIV-2 isolates.

While HIV-2 is related to HIV-1 by its morphology, its tropism and its in vitro cytopathic effect on CD4 (T4) positive cell lines and lymphocytes, HIV-2 differs from previously described human retroviruses known to be responsible for AIDS. Moreover, the proteins of HIV-1 and 2 have different sizes and their serological cross-reactivity is restricted mostly to the major core protein, as the envelope glycoproteins of HIV-2 are not immune precipitated by HIV-1-positive sera except in some cases where very faint cross-reactivity can be detected. Since a

significant proportion of the HIV infected patients lack antibodies to the major core protein of their infecting virus, it is important to include antigens to both HIV-1 and HIV-2 in an effective serum test for the diagnosis of the infection by these viruses.

HIV-2 was first discovered in the course of serological research on patients native to Guinea-Bissau who exhibited clinical and immunological symptoms of AIDS and from whom sero-negative or weakly sero-positive reactions to tests using an HIV-1 lysate were obtained. Further clinical studies on these patients isolated viruses which were subsequently named "LAV-II."

One LAV-II isolate, subsequently referred to as LAV-II MIR, was deposited at the Collection Nationale des Cultures de Micro-Organismes (CNCM) at the Institut Pasteur in Paris, France on December 19, 1985 under Accession No. I-502 and has also been deposited at the British ECA CC under No. 87.001.001 on January 9, 1987. A second LAV-II isolate was deposited at CNCM on February 21, 1986 under Accession No. I-532 and has also been deposited at the British ECA CC under No. 87.001.002 on January 9, 1987. This second isolate has been subsequently referred to as LAV-II ROD. Other isolates deposited at the CNCM on December 19, 1986 are HIV-2 IRMO (No. I-642) and HIV-2 EHO (No. I-643). Several additional isolates have been obtained from West African patients, some of whom have AIDS, others with AIDS-related conditions and others with no AIDS symptoms. All of these viruses have been isolated on normal human lymphocyte cultures and some

of them were thereafter propagated on lymphoid tumor cell lines such as CEM and MOLT.

Due to the sero-negative or weak sero-positive results obtained when using kits designed to identify HIV-1 infections in the diagnosis of these new patients with HIV-2 disease, it has been necessary to devise a new diagnostic kit capable of detecting HIV-2 infection, either by itself or in combination with an HIV-1 infection. The present inventors have, through the development of cloned DNA sequences analogous to at least a portion of the genomic RNA of LAV-II ROD viruses, created the materials necessary for the development of such kits.

Summary of the Invention

As noted previously, the present invention relates to the cloned nucleotide sequences homologous or identical to at least a portion of the genomic RNA of HIV-2 viruses and to polypeptides encoded by the same. The present invention also relates to kits capable of diagnosing an HIV-2 infection.

Thus, a main object of the present invention is to provide a kit capable of diagnosing an infection caused by the HIV-2 virus. This kit may operate by detecting at least a portion of the RNA genome of the HIV-2 virus or the provirus present in the infected cells through hybridization with a DNA probe or it may operate through the immunodiagnostic detection of polypeptides unique to the HIV-2 virus.

Additional objects and advantages of the present invention will be set forth in part in the description which follows, or

may be learned from practice of the invention. The objects and advantages may be realized and attained by means of the instrumentalities and combinations particularly pointed out in the appended claims.

To achieve these objects and in accordance with the purposes of the present invention, cloned DNA sequences related to the entire genomic RNA of the LAV-II virus are set forth. These sequences are analogous specifically to the entire genome of the LAV-II ROD strain.

To further achieve the objects and in accordance with the purposes of the present invention, a kit capable of diagnosing an HIV-2 infection is described. This kit, in one embodiment, contains the cloned DNA sequences of this invention which are capable of hybridizing to viral RNA or analogous DNA sequences to indicate the presence of an HIV-2 infection. Different diagnostic techniques can be used which include, but are not limited to:

(1) Southern blot procedures to identify viral DNA which may or may not be digested with restriction enzymes; (2) Northern blot techniques to identify viral RNA extracted from cells; and (3) dot blot techniques, i.e., direct filtration of the sample through an ad hoc membrane such as nitrocellulose or nylon without previous separation on agarose gel. Suitable material for dot blot technique could be obtained from body fluids including, but not limited to, serum and plasma, supernatants from culture cells, or cytoplasmic extracts obtained after cell lysis and removal of membranes and nuclei of the cells by

ultra-centrifugation as accomplished in the "CYTODOT" procedure as described in a booklet published by Schleicher and Schull.

In an alternate embodiment, the kit contains the polypeptides created using these cloned DNA sequences. These polypeptides are capable of reacting with antibodies to the HIV-2 virus present in sera of infected individuals, thus yielding an immunodiagnostic complex.

To further achieve the objects of the invention, a vaccinating agent is provided which comprises at least one peptide selected from the polypeptide expression products of the viral DNA in admixture with suitable carriers, adjuvents stabilizers.

It is understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate one embodiment of the invention and, together with the description, serve to explain the principles of the invention.

Brief Description of the Drawings

Figure 1 generally depicts the nucleotide sequence of a cloned complementary DNA (cDNA) to the genomic RNA of HIV-2. Figure 1A depicts the genetic organization of HIV-1, position of the HIV-1 HindIII fragment used as a probe to screen the cDNA library, and restriction map of the HIV-2 cDNA clone, E2. Figure 1B depicts the nucleotide sequence of the 3' end of HIV-2.

The corresponding region of the HIV-1 LTR was aligned using the Wilbur and Lipman algorithm (window: 10; K-tuple: 7; gap penalty: 3) as described by Wilbur and Lipman in Proc. Natl. Acad. Sci. USA 80: 726-730 (1983), specifically incorporated herein by reference. The U3-R junction in HIV-1 is indicated and the poly A addition signal and potential TATA promoter regions are boxed. In Figure 1B, the symbols B, H, Ps and Pv refer to the restriction sites BamHI, HindIII, PstI and PvuII, respectively.

Figure 2 generally depicts the HIV-2 specificity of the E2 clone. Figure 2A and B specifically depict a Southern blot of DNA extracted from CEM cells infected with the following isolates: HIV-2_{ROD} (a,c), HIV-2_{DUL} (b,d), and HIV-1_{BRU} (e,f). DNA in lanes a,b,f was Pst I digested; in c,d,e DNA was undigested. Figure 2C and D specifically depict dot blot hybridization of pelleted virions from CEM cells infected by the HIV-1_{BRU}(1), Simian Immunodeficiency Virus (SIV) isolate Mm 142-83 (3), HIV-2_{DUL} (4), HIV-2_{ROD} (5), and HIV-1_{ELI} (6). Dot 2 is a pellet from an equivalent volume of supernatant from uninfected CEM. Thus, Figure 2A and C depicts hybridization with the HIV-2 cDNA (E2) and Figure 2B and D depicts hybridization to an HIV-1 probe consisting of a 9Kb SacI insert from HIV-1 BRU(clone lambda J 19).

Figure 3 generally depicts a restriction map of the HIV-2 ROD genome and its homology to HIV-1. Figure 3A specifically depicts the organization of three recombinant phage lambda clones, ROD 4, ROD 27, and ROD 35. In Figure 3A, the open boxes

represent viral sequences, the LTR are filled, and the dotted boxes represent cellular flanking sequences (not mapped). Only some characteristic restriction enzyme sites are indicated. λ ROD 27 and λ ROD 35 are derived from integrated proviruses while λ ROD 4 is derived from a circular viral DNA. The portion of the lambda clones that hybridizes to the cDNA E2 is indicated below the maps. A restriction map of the λ ROD isolate was reconstructed from these three lambda clones. In this map, the restriction sites are identified as follows: B: BamHI; E: EcoRI; H: HindIII; K: KpnI; Ps: PstI; Pv: PvuII; S: SacI; X: XbaI. R and L are the right and left BamHI arms of the lambda L47.1 vector.

Figure 3B specifically depicts dots 1-11 which correspond to the single-stranded DNA form of M13 subclones from the HIV-1_{BRU} cloned genome (λ J19). Their size and position on the HIV-1 genome, determined by sequencing is shown below the figure. Dot 12 is a control containing lambda phage DNA. The dot-blot was hybridized in low stringency conditions as described in Example 1 with the complete lambda λ ROD 4 clone as a probe, and successively washed in 2x SSC, 0.1% SDS at 25°C. (T_m -42°C), 1x SSC, 0.1% SDS at 60°C. (T_m -20°C.), and 0.1x SSC, 0.1% SDS at 60°C. (T_m -3°C) and exposed overnight. A duplicate dot blot was hybridized and washed in stringent conditions (as described in Example 2) with the labelled lambda J19 clone carrying the complete HIV-1_{BRU} genome. HIV-1 and HIV-2 probes were labelled the same specific activity (10^8 cpm/ g.).

Figure 4 generally depicts the restriction map polymorphism in different HIV-2 isolates and shows comparison of HIV-2 to SIV. Figure 4A specifically depicts DNA (20 ug. per lane) from CEM cells infected by the isolate HIV-2_{DUL} (panel 1) or peripheral blood lymphocytes (PBL) infected by the isolates HIV-2_{GOM} (panel 2) and HIV-2_{MIR} (panel 3) digested with: EcoRI (a), PstI (b), and HindIII (c). Much less viral DNA was obtained with HIV-2 isolates propagated on PBL. Hybridization and washing were in stringent conditions, as described in Example 2, with 10⁶ cpm/ml. of each of the E2 insert (cDNA) and the 5 kb. HindIII fragment of λ ROD 4, labelled to 10⁹ cpm/ug.

Figure 4B specifically depicts DNA from HUT 78 (a human T lymphoid cell line) cells infected with STLV3 MAC isolate Mm 142-83. The same amounts of DNA and enzymes were used as indicated in panel A. Hybridization was performed with the same probe as in A, but in non-stringent conditions. As described in Example 1 washing was for one hour in 2x SSC, 0.1% SDS at 40°C (panel 1) and after exposure, the same filter was re-washed in 0.1x SSC, 0.1% SDS at 60°C. (panel 2). The autoradiographs were obtained after overnight exposition with intensifying screens.

Figure 5 depicts the position of derived plasmids from λ ROD 27, λ ROD 35 and λ ROD 4.

Detailed Description of the Preferred Embodiments

Reference will now be made in detail to the presently preferred embodiments of the invention, which, together with the following examples, serve to explain the principles of the invention.

The genetic structure of the HIV-2 virus has been analyzed by molecular cloning according to the method set forth herein and in the Examples. A restriction map of the genome of this virus is included in Figure 4. In addition, the partial sequence of a cDNA complementary to the genomic RNA of the virus has been determined. This cDNA sequence information is included in Figure 1.

Also contained herein is data describing the molecular cloning of the complete 9.5 kb genome of HIV-2, data describing the observation of restriction map polymorphism between different isolates, and an analysis of the relationship between HIV-2 and other human and simian retroviruses. From the totality of these data, diagnostic probes can be discerned and prepared.

Generally, to practice one embodiment of the present invention, a series of filter hybridizations of the HIV-2 RNA genome with probes derived from the complete cloned HIV-1 genome and from the gag and pol genes were conducted. These hybridizations yielded only extremely weak signals even in conditions of very low stringency of hybridization and washing. Thus, it was found to be difficult to assess the amount of HIV-2 viral and proviral DNA in infected cells by Southern blot techniques.

Therefore, a complementary DNA (cDNA) to the HIV-2 genomic RNA initially was cloned in order to provide a specific hybridization probe. To construct this cDNA, an oligo (dT) primed cDNA first-strand was made in a detergent-activated endogenous reaction using HIV-2 reverse transcriptase with virions purified

from supernatants of infected CEM cells. The CEM cell line is a lymphoblastoid CD4+ cell line described by G.E. Foley et al. in Cancer 18: 522-529 (1965), specifically incorporated herein by reference. The CEM cells used were infected with the isolate ROD and were continuously producing high amounts of HIV-2.

After second-strand synthesis, the cDNAs were inserted into the M 13 tg 130 bacteriophage vector. A collection of 10^4 M13 recombinant phages was obtained and screened in situ with an HIV-1 probe spanning 1.5 kb. of the 3' end of the LAV_{BRU} isolate (depicted in Figure 1A). Some 50 positive plaques were detected, purified, and characterized by end sequencing and cross-hybridizing the inserts. This procedure is described in more detail in Example 1 and in Figure 1.

The different clones were found to be complementary to the 3' end of a polyadenylated RNA having the AATAAA signal about 20 nucleotides upstream of the poly A tail, as found in the long terminal repeat (LTR) of HIV-1. The LTR region of HIV-1 has been described by S. Wain Hobson et al. in Cell 40: 9-17 (1985), specifically incorporated herein by reference. The portion of the HIV-2 LTR that was sequenced was related only distantly to the homologous domain in HIV-1 as demonstrated in Figure 1 B. Indeed, only about 50% of the nucleotides could be aligned and about a hundred insertions/deletions need to be introduced. In comparison, the homology of the corresponding domains in HIV-1 isolates from USA and Africa is greater than 95% and no insertions or deletions are seen.

The largest insert of this group of M13 clones was a 2 kb. clone designated E2. Clone E2 was used as a probe to demonstrate its HIV-2 specificity in a series of filter hybridization experiments. Firstly, this probe could detect the genomic RNA of HIV-2 but not HIV-1 in stringent conditions as shown in Figure 2, C and D. Secondly, positive signals were detected in Southern blots of DNA from cells infected with the ROD isolate as well as other isolates of HIV-2 as shown in Figure 2, A and Figure 4, A. No signal was detected with DNA from uninfected cells or HIV-1 infected cells, confirming the exogenous nature of HIV-2. In undigested DNA from HIV-2 infected cells, an approximately 10 kb. species, probably corresponding to linear unintegrated viral DNA, was principally detected along with a species with an apparent size of 6 kb., likely to be the circular form of the viral DNA. Conversely, rehybridization of the same filter with an HIV-1 probe under stringent conditions showed hybridization to HIV-1 infected cells only as depicted in Figure 2, B.

To isolate the remainder of the genome of HIV-2, a genomic library in lambda phage L47.1 was constructed. Lambda phage L47.1 has been described by W.A.M. Loenen et al. in Gene 10: 249-259 (1980), specifically incorporated herein by reference. The genomic library was constructed with a partial Sau3AI restriction digest of the DNA from the CEM cell line infected with HIV-2_{ROD}.

About 2×10^6 recombinant plaques were screened in situ with labelled insert from the E2 cDNA clone. Ten recombinant phages

were detected and plaque purified. Of these phages, three were characterized by restriction mapping and Southern blot hybridization with the E2 insert and probes from its 3' end (LTR) or 5' end (envelope), as well as with HIV-1 subgenomic probes. In this instance, HIV-1 probes were used under non-stringent conditions.

A clone carrying a 9.5 kb. insert and derived from a circular viral DNA was identified as containing the complete genome and designated λ ROD 4. Two other clones, λ ROD 27 and λ ROD 35 were derived from integrated proviruses and found to carry an LTR and cellular flanking sequences and a portion of the viral coding sequences as shown in Figure 3, A.

Fragments of the lambda clones were subcloned into a plasmid vector p UC 18.

Plasmid pROD 27-5' is derived from λ ROD 27 and contains the 5' 2Kb of the HIV-2 genome and cellular flanking sequences (5' LTR and 5' viral coding sequences to the EcoRI site)

Plasmid p ROD 4-8 is derived from λ ROD 4 and contains the about 5Kb HindIII fragment that is the central part of the HIV-2 genome.

Plasmid pROD 27-5' and p ROD 4.8 inserts overlap.

Plasmid pROD 4.7 contains a HindIII 1.8 Kb fragment from λ ROD 4. This fragment is located 3' to the fragment subcloned into pROD 4.8 and contains about 0.8 Kb of viral coding sequences and the part of the lambda phage (λ L47.1) left arm located between the BamHI and HindIII cloning sites.

Plasmid pROD 35 contains all the HIV-2 coding sequences 3' to the EcoRI site, the 3' LTR and about 4 Kb of cellular flanking sequences.

Plasmid pROD 27-5' and pROD 35 in E. coli strain HB 101 are deposited respectively under No. 1-626 and 1-633 at the CNCM, and have also been deposited at the NCIB (British Collection). These plasmids are depicted in Figure 5. Plasmids pROD 4-7 and pROD 4-8 in E. coli strain TG1 are deposited respectively under No. 1-627 and 1-628 at the CNCM.

To reconstitute the complete HIV-2 ROD genome, pROD 35 is linearized with EcoRI and the EcoRI insert of pROD 27-5' is ligated in the correct orientation into this site.

The relationship of HIV-2 to other human and simian retroviruses was surmised from hybridization experiments. The relative homology of the different regions of the HIV-1 and 2 genomes was determined by hybridization of fragments of the cloned HIV-1 genome with the labelled λ ROD 4 expected to contain the complete HIV-2 genome (Figure 3, B). Even in very low stringency conditions (T_m -42°C.), the hybridization of HIV-1 and 2 was restricted to a fraction of their genomes, principally the gag gene (dots 1 and 2), the reverse transcriptase domain in pol (dot 3), the end of pol and the Q (or sor) genes (dot 5) and the F gene (or 3' orf) and 3' LTR (dot 11). The HIV-1 fragment used to detect the HIV-2 cDNA clones contained the dot 11 subclone, which hybridized well to HIV-2 under non-stringent conditions. Only the signal from dot 5 persisted after stringent washing. The envelope gene,

the region of the tat gene and a part of pol thus seemed very divergent. These data, along with the LTR sequence obtained (Figure 1, B), indicated that HIV-2 is not an envelope variant of HIV-1, as are African isolates from Zaire described by Alizon et al., Cell 40:63-74 (1986).

It was observed that HIV-2 is related more closely to the Simian Immunodeficiency Virus (SIV) than it is to HIV-1. This correlation has been described by F. Clavel et al. in C.R. Acad. Sci. (Paris) 302: 485-488 (1986) and F. Clavel et al. in Science 233: 343-346 (1986), both of which are specifically incorporated herein by reference. Simian Immunodeficiency Virus (also designated Simian T-cell Lymphotropic Virus Type 3, STLV-3) is a retrovirus first isolated from captive macaques with an AIDS-like disease in the USA. This simian virus has been described by M.D. Daniel et al. in Science 228: 1201-1204 (1985), specifically incorporated herein by reference.

All the SIV proteins, including the envelope, are immune precipitated by sera from HIV-2 infected patients, whereas the serological cross-reactivity of HIV-1 to 2 is restricted to the core proteins. However SIV and HIV-2 can be distinguished by slight differences in the apparent molecular weight of their proteins.

In terms of nucleotide sequence, it also appears that HIV-2 is closely related to SIV. The genomic RNA of SIV can be detected in stringent conditions as shown in Figure 2, C by HIV-2 probes corresponding to the LTR and 3' end of the genome (E2) or

to the gag or pol genes. Under the same conditions, HIV-1 derived probes do not detect the SIV genome as shown in Figure 2, D.

In Southern blots of DNA from SIV-infected cells, a restriction pattern clearly different from HIV-2_{ROD} and other isolates is seen. All the bands persist after a stringent washing, even though the signal is considerably weakened, indicating a sequence homology throughout the genomes of HIV-2 and SIV. It has recently been shown that baboons and macaques could be infected experimentally by HIV-2, thereby providing an interesting animal model for the study of the HIV infection and its preventive therapy. Indeed, attempts to infect non-human primates with HIV-1 have been successful only in chimpanzees, which are not a convenient model.

From an initial survey of the restriction maps for certain of the HIV-2 isolates obtained according to the methods described herein, it is already apparent that HIV-2, like HIV-1, undergoes restriction site polymorphism. Figure 4 A depicts examples of such differences for three isolates, all different one from another and from the cloned HIV-2_{ROD}. It is very likely that these differences at the nucleotide level are accompanied by variations in the amino-acid sequence of the viral proteins, as evidenced in the case of HIV-1 and described by M. Alizon et al. in Cell 46: 63-74 (1986), specifically incorporated herein by reference. It is also to be expected that the various isolates of HIV-2 will exhibit amino acid heterogeneities. See, for

example, Clavel et al., Nature 324 (18):691-695 (1986), specifically incorporated herein by reference.

Further, the characterization of HIV-2 will also delineate the domain of the envelope glycoprotein that is responsible for the binding of the surface of the target cells and the subsequent internalization of the virus. This interaction was shown to be mediated by the CD4 molecule itself in the case of HIV-1 and similar studies tend to indicate that HIV-2 uses the same receptor. Thus, although there is wide divergence between the env genes of HIV-1 and 2, small homologous domains of the envelopes of the two HIV could represent a candidate receptor binding site. This site could be used to raise a protective immune response against this group of retroviruses.

From the data discussed herein, certain nucleotide sequences have been identified which are capable of being used as probes in diagnostic methods to obtain the immunological reagents necessary to diagnose an HIV-2 infection. In particular, these sequences may be used as probes in hybridization reactions with the genetic material of infected patients to indicate whether the RNA of the HIV-2 virus is present in these patient's lymphocytes or whether an analogous DNA is present. In this embodiment, the test methods which may be utilized include Northern blots, Southern blots and dot blots. One particular nucleotide sequence which may be useful as a probe is the combination of the 5 kb. HindIII fragment of ROD 4 and the E2 cDNA used in Figure 4.

In addition, the genetic sequences of the HIV-2 virus may be used to create the polypeptides encoded by these sequences. Specifically, these polypeptides may be created by expression of the cDNA obtained according to the teachings herein in hosts such as bacteria, yeast or animal cells. These polypeptides may be used in diagnostic tests such as immunofluorescence assays (IFA), radioimmunoassays (RIA) and Western Blot tests.

Moreover, it is also contemplated that additional diagnostic tests, including additional immunodiagnostic tests, may be developed in which the DNA probes or the polypeptides of this invention may serve as one of the diagnostic reagents. The invention described herein includes these additional test methods.

In addition, monoclonal antibodies to these polypeptides or fragments thereof may be created. The monoclonal antibodies may be used in immunodiagnostic tests in an analogous manner as the polypeptides described above.

The polypeptides of the present invention may also be used as immunogenic reagents to induce protection against infection by HIV-2 viruses. In this embodiment, the polypeptides produced by recombinant-DNA techniques would function as vaccine agents.

Also, the polypeptides of this invention may be used in competitive assays to test the ability of various antiviral agents to determine their ability to prevent the virus from fixing on its target.

Thus, it is to be understood that application of the teachings of the present invention to a specific problem or environment will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and representative processes for their isolation and manufacture appear above and in the following examples.

EXAMPLES

Example 1: Cloning of a cDNA Complementary to
 Genomic RNA From HIV-2 Virions

HIV-2 virions were purified from 5 liters of supernatant from a culture of the CEM cell line infected with the ROD isolate and a cDNA first strand using oligo (dT) primer was synthesized in detergent activated endogenous reaction on pelleted virus, as described by M. Alizon et al. in Nature, 312: 757-760 (1984), specifically incorporated herein by reference. RNA-cDNA hybrids were purified by phenol-chloroform extraction and ethanol precipitation. The second-strand cDNA was created by the DNA polymerase I/RNAase H method of Gubler and Hoffman in Gene, 25: 263-269 (1983), specifically incorporated herein by reference, using a commercial cDNA synthesis kit obtained from Amersham. After attachment of EcoRI linkers (obtained from Pharmacia), EcoRI digestion, and ligation into EcoRI-digested dephosphorylated M13 tg 130 vector (obtained from Amersham), a cDNA library was obtained by transformation of the E. coli TGI strain. Recombinant plaques (10^4) were screened in situ on replica filters with the 1.5 kb. HindIII fragment from clone J19,

corresponding to the 3' part of the genome of the LAVBRU isolate of HIV-1, ^{32}P labelled to a specific activity of 10^9 cpm ug. The filters were prehybridized in 5 x SSC, 5 x Denhardt solution, 25% formamide, and denatured salmon sperm DNA (100 ug/ ml.) at 37°C. for 4 hours and hybridized for 16 hours in the same buffer (T_m -42°C.) plus 4×10^7 cpm of the labelled probe (10^6 cpm/ml. of hybridization buffer). The washing was done in 5 x SSC, 0.1% SDS at 25°C. for 2 hours. 20 x SSC is 3M NaCl, 0.3M Na citrate. Positive plaques were purified and single-stranded M13 DNA prepared and end-sequenced according to the method described in Proc. Nat'l. Acad. Sci. USA, 74: 5463-5467 (1977) of Sanger et al.

Example 2: Hybridization of DNA from HIV-1 and
HIV-2 Infected Cells and RNA from HIV-1
and 2 and SIV Virons With a Probe
Derived From an HIV-2 Cloned cDNA

DNA was extracted from infected CEM cells continuously producing HIV-1 or 2. The DNA digested with 20 ug of PstI digested with or undigested, was electrophoresed on a 0.8% agarose gel, and Southern-transferred to nylon membrane. Virion dot-blot were prepared in duplicate, as described by F. Clavel et al. in Science 233: 343-346 (1986), specifically incorporated herein by reference, by pelleting volumes of supernatant corresponding to the same amount of reverse transcriptase activity.

Prehybridization was done in 50% formamide, 5 x SSC, 5 x Denhardt solution, and 100 mg./ml. denatured salmon sperm DNA for 4 hours at 42°C. Hybridization was performed in the same buffer plus 10% Dextran sulphate, and 10^6 cpm/ml. of the labelled E2 insert

(specific activity 10^9 cpm/ug.) for 16 hours at 42°C. Washing was in 0.1 x SSC, 0.1% SDS for 2 x 30 mn. After exposition for 16 hours with intensifying screens, the Southern blot was dehybridized in 0.4 N NaOH, neutralized, and rehybridized in the same conditions to the HIV-1 probe labelled to 10^9 cpm/ug.

Example 3: Cloning in Lambda Phage of the
 Complete Provirus DNA of HIV-2

DNA from the HIV-2_{ROD} infected CEM (Figure 2, lanes a and c) was partially digested with Sau3AI. The 9-15 kb. fraction was selected on a 5-40% sucrose gradient and ligated to BamHI arms of the lambda L47.1 vector. Plaques (2×10^6) obtained after in vitro packaging and plating on E. coli LA 101 strain were screened in situ with the insert from the E2 cDNA clone. Approximately 10 positive clones were plaque purified and propagated on E. coli C600 recBC. The ROD 4, 27, and 35 clones were amplified and their DNA characterized by restriction mapping and Southern blotting with the HIV-2 cDNA clone under stringent conditions, and gag-pol probes from HIV-1 used under non stringent conditions.

Example 4: **Complete Genomic Sequence of**
the ROD HIV-2 Isolate

Experimental analysis of the HIV-2 ROD isolate yielded the following sequence which represents the complete genome of this HIV-2 isolate. Genes and major expression products identified within the following sequence are indicated by nucleotides numbered below:

1) GAG gene (546-2111) expresses a protein product having a molecular weight of around 55Kd and is cleaved into the following proteins:

- a) p 16 (546-950)
 - b) p 26 (951-1640)
 - c) p 12 (1701-2111)
- 2) polymerase (1829-4936)
 - 3) Q protein (4869-5513)
 - 4) R protein (5682-5996)
 - 5) X protein (5344-5679)
 - 6) Y protein (5682-5996)
 - 7) Env protein (6147-8720)
 - 8) F protein (8557-9324)
 - 9) TAT gene (5845-6140 and 8307-8400) is expressed by two exons separated by introns.
 - 10) ART protein (6071-6140 and 8307-8536) is similarly the expression product of two exons.
 - 11) LTR:R (1-173 and 9498-9671)

12) U5 (174-299)

13) U3 (8942-9497)

It will be known to one of skill in the art that the absolute numbering which has been adopted is not essential. For example, the nucleotide within the LTR which is designated as "1" is a somewhat arbitrary choice. What is important is the sequence information provided.

GGTCGCTCTGCGGAGAGGCTGGCAGATTGAGCCCTGGGAGGTTCTCTCCAGCACTAGCAG
GTAGAGCCTGGGTGTTCCCTGCTAGACTCTCACCAGCACTTGGCCGGTGCTGGGCAGACG
100
GCCCCACGCTTGCTTGCTTAAAAACCTCTTAATAAAGCTGCCAGTTAGAAGCAAGTTAAG
TGTGTGCTCCCATCTCTCCTAGTCGCGCCCTGGTCATTGCGGTGTTACCTGAGTAACAAG
200
ACCCTGGTCTGTTAGGACCCTTCTTGCTTTGGGAAACCGAGGCAGGAAAATCCCTAGCAG
300
GTTGGCGCCTGAACAGGGACTTGAAGAAGACTGAGAAGTCTTGAAACACGGCTGAGTGAA
GGCAGTAAGGGCGGCAGGAACAAACCACGACGGAGTGCTCCTAGAAAGGCGGGGCGGAG
400
GTACCAAAGGCAGCGTGTGGAGCGGGAGGAGAAGAGGCCCTCCGGGTGAAGCTAAGTACCT
ACACCAAAAACTGTAGCCGAAAGGCCTTGCTATCCTACCTTTAGACAGGTAGAAGATTGT
500
MetGlyAlaArgAsnSerValLeuArgGlyLysLysAlaAspGluLeuGluArgIle
GGGAGATGGGCGCGAGAAACTCCGTCTTGAGAGGGAAAAAAGCAGATGAATTAGAAAGAA
600
ArgLeuArgProGlyGlyLysLysLysTyrArgLeuLysHisIleValTrpAlaAlaAsn
TCAGGTTACGGCCCCGGCGGAAAGAAAAAGTACAGGCTAAACATATTGTGTGGCCAGCGA
LysLeuAspArgPheGlyLeuAlaGluSerLeuLeuGluSerLysGluGlyCysGlnLys
700
ATAAATTGGACAGATTCCGATTAGCAGAGAGCCTGTTGGAGTCAAAAGAGGGTTGTCAAA
IleLeuThrValLeuAspProMetValProThrGlySerGluAsnLeuLysSerLeuPhe
AAATTCTTACAGTTTTAGATCCAATGGTACCGACAGGTTTCAGAAAATTTAAAAAGTCTTT
AsnThrValCysValIleTrpCysIleHisAlaGluGluLysValLysAspThrGluGly
800
TTAATACTGTCTGCGTCATTITGGTGCATACACGCAGAAGAGAAAGTGAAGATACTGAAG
AlaLysGlnIleValArgArgHisLeuValAlaGluThrGlyThrAlaGluLysMetPro
900
GAGCAAAACAAATAGTGGCGAGACATCTAGTGCCAGAAACAGGAACTGCAGAGAAAATGC
SerThrSerArgProThrAlaProSerSerGluLysGlyGlyAsnTyrProValGlnHis
CAAGCACAAGTAGACCAACAGCACCATCTAGCGAGAAGGGAGGAAATTACCCAGTCAAC
ValGlyGlyAsnTyrThrHisIleProLeuSerProArgThrLeuAsnAlaTrpValLys
1000
ATGTAGGCGGCAACTACACCCATATACCGCTCAGTCCCCGAACCCTAAATGCCTGGGTAA
LeuValGluGluLysLysPheGlyAlaGluValValProGlyPheGlnAlaLeuSerGlu
AATTAGTAGAGGAAAAAAGTTCGGGGCAGAAGTAGTCCAGGATTTCAGGCACTCTCAG

GlyCysThrProTyrAspIleAsnGlnMetLeuAsnCysValGlyAspHisGlnAlaAla
 AAGGCTGCACGCCCTATGATATCAACCAATGCTTAATTGTGTGGCGGACCATCAAGCAG
 1100
 MetGlnIleIleArgGluIleIleAsnGluGluAlaAlaGluTrpAspValGlnHisPro
 CCATGCAGATAATCAGGCACATTATCAATGAGGAAGCAGCAGAATGGGATGTGCAACATC
 1200
 IleProGlyProLeuProAlaGlyGlnLeuArgGluProArgGlySerAspIleAlaGly
 CAATACCAGGCCCTTACCAGCGGGCAGCTTAGAGAGCCAAGGGGATCTGACATAGCAG
 ThrThrSerThrValGluGluGlnIleGlnTrpMetPheArgProGlnAsnProValPro
 CGACAACAAGCACAGTAGAAGAACAGATCCAGTGGATGTTTAGGCCACAAAATCCTGTAC
 1300
 ValGlyAsnIleTyrArgArgTrpIleGlnIleGlyLeuGlnLysCysValArgMetTyr
 CAGTAGGAAACATCTATAGAAGATGGATCCAGATAGGATTGCAGAAGTGTGTCAGGATGT
 AsnProThrAsnIleLeuAspIleLysGlnGlyProLysGluProPheGlnSerTyrVal
 ACAACCCGACCAACATCCTAGACATAAAACAGGGACCAAAGGAGCCGTTCCAAAGCTATG
 1400
 AspArgPheTyrLysSerLeuArgAlaGluGlnThrAspProAlaValLysAsnTrpMet
 TAGATAGATTCTACAAAAGCTTGAGGGCAGAACAACAGATCCAGCAGTGAAGAATTGGA
 1500
 ThrGlnThrLeuLeuValGlnAsnAlaAsnProAspCysLysLeuValLeuLysGlyLeu
 TGACCCAAACACTGCTAGTACAAAATGCCAACCCAGACTGTAAATTAGTCTAAAAGGAC
 GlyMetAsnProThrLeuGluGluMetLeuThrAlaCysGlnGlyValGlyGlyProGly
 TAGGGATGAACCTACCTTAGAAGAGATGCTGACCGCCTGTCAGGGGGTAGGTGGGCCAG
 1600
 GlnLysAlaArgLeuMetAlaGluAlaLeuLysGluValIleGlyProAlaProIlePro
 GCCAGAAAGCTAGATTAATGGCAGAGGCCCTGAAAGAGGTCATAGGACCTGCCCCCTATCC
 PheAlaAlaAlaGlnGlnArgLysAlaPheLysCysTrpAsnCysGlyLysGluGlyHis
 CATTCCGACGAGCCAGCAGAGAAAGGCATTTAAATGCTGGAAGTGTGCAAAGGAAGGGC
 1700
 SerAlaArgGlnCysArgAlaProArgArgGlnGlyCysTrpLysCysGlyLysProGly
 ACTCGGCAAGACAATGCCGAGCACCTAGAAGGCAGGGCTGCTGGAAGTGTGGTAAGCCAG
 1800
 ThrGlyArgPhePheArgThrGlyProLeuGly
 HisIleMetThrAsnCysProAspArgGlnAlaGlyPheLeuGlyLeuGlyProTrpGly
 GACACATCATGACAAACTGCCCAGATAGACAGGCAGGTTTTTTAGGACTGGGCCCTTGGG
 LysGluAlaProGlnLeuProArgGlyProSerSerAlaGlyAlaAspThrAsnSerThr
 LysLysProArgAsnPheProValAlaGlnValProGlnGlyLeuThrProThrAlaPro
 GAAAGAAGCCCCGCAACTTCCCCGTGGCCCAAGTTCGCCAGGGGCTGACACCAACAGCAC
 1900
 ProSerGlySerSerSerGlySerThrGlyGluIleTyrAlaAlaArgGluLysThrGlu
 ProValAspProAlaValAspLeuLeuGluLysTyrMetGlnGlnGlyLysArgGlnArg
 CCCAGTGGATCCAGCAGTGGATCTACTGGAGAAATATATCCAGCAACGGAAAAACACAGA
 ArgAlaGluArgGluThrIleGlnGlySerAspArgGlyLeuThrAlaProArgAlaGly
 GluGlnArgGluArgProTyrLysGluValThrGluAspLeuLeuHisLeuGluGlnGly
 GAGAGCAGAGAGAGACCATACAAGGAAGTGACAGAGGACTTACTGCACCTCGAGCAGG
 2000
 GlyAspThrIleGlnGlyAlaThrAsnArgGlyLeuAlaAlaProGlnPheSerLeuTrp
 GluThrProTyrArgGluProProThrGluAspLeuLeuHisLeuAsnSerLeuPheGly
 GGGAGACACCATACAGGGAGCCACCAACAGAGGACTTGCTGCACCTCAATTCTCTTTG
 2100

LysArgProValValThrAlaTyrIleGluGlyGlnProValGluValLeuLeuAspThr
 LysAspGln
 GAAAAGACCAGTAGTCACAGCATACATTGAGGGTCAGCCAGTAGAAGTCTTGTTAGACAC
 GlyAlaAspAspSerIleValAlaGlyIleGluLeuGlyAsnAsnTyrSerProLysIle
 AGGGGCTGACGACTCAATAGTAGCAGGAATAGAGTTAGGGAACAATTATAGCCCCAAAAAT
 2200
 ValGlyGlyIleGlyGlyPheIleAsnThrLysGluTyrLysAsnValGluIleGluVal
 AGTAGGGGGAATAGGGGGATTTCATAAATACCAAGGAATATAAAAAATGTAGAAATAGAAGT
 LeuAsnLysLysValArgAlaThrIleMetThrGlyAspThrProIleAsnIlePheGly
 TCTAAATAAAAAAGGTACGGGCCACATAATGACAGGGGACACCCCAATCAACATTTTTTGG
 2300
 ArgAsnIleLeuThrAlaLeuGlyMetSerLeuAsnLeuProValAlaLysValGluPro
 CAGAAATATTCTGACAGCCTTAGGCATGTCATTAAATCTACCAGTGGCCAAAGTAGAGCC
 2400
 IleLysIleMetLeuLysProGlyLysAspGlyProLysLeuArgGlnTrpProLeuThr
 AATAAAAAATAATGCTAAAGCCAGGGAAAGATGACCCAAACTGAGACAATGGCCCTTAAC
 LysGluLysIleGluAlaLeuLysGluIleCysGluLysMetGluLysGluGlyGlnLeu
 AAAAGAAAAAATAGAAGCACTAAAAGAAATCTGTGAAAAAATGGAAAAAGAAGGCCAGCT
 2500
 GluGluAlaProProThrAsnProTyrAsnThrProThrPheAlaIleLysLysLysAsp
 AGAGGAAGCACCTCCAACATAATCCTTATAATACCCCCACATTTGCAATCAAGAAAAAGGA
 LysAsnLysTrpArgMetLeuIleAspPheArgGluLeuAsnLysValThrGlnAspPhe
 CAAAAACAATGGAGCATGCTAATAGATTTTCAGAGAACTAAACAAGGTAAGTCAAGATTT
 2600
 ThrGluIleGlnLeuGlyIleProHisProAlaGlyLeuAlaLysLysArgArgIleThr
 CACAGAAATTCAGTTAGGAATTCCACACCCAGCAGGGTTGGCCAAGAAGAGAAGAATTAC
 2700
 ValLeuAspValGlyAspAlaTyrPheSerIleProLeuHisGluAspPheArgProTyr
 TGTACTAGATGTACGGGATGCTTACTTTTCCATACCACTACATGAGGACTTTAGACCATA
 ThrAlaPheThrLeuProSerValAsnAsnAlaGluProGlyLysArgTyrIleTyrLys
 TACTGCATTTACTCTACCATCAGTGAACAATGCAGAACCAGGAAAAAGATACATATATAA
 2800
 ValLeuProGlnGlyTrpLysGlySerProAlaIlePheGlnHisThrMetArgGlnVal
 AGTCTTGGCACAGGGATGGAAGGGATCACCAGCAATTTTTTCAACACACAATGAGACAGGT
 LeuGluProPheArgLysAlaAsnLysAspValIleIleIleGlnTyrMetAspAspIle
 ATTAGAACCATTTCAGAAAAGCAAACAAGGATGTCATTATCATTTCAGTACATGGATGATAT
 2900
 LeuIleAlaSerAspArgThrAspLeuGluHisAspArgValValLeuGlnLeuLysGlu
 CTTAATAGCTAGTGACAGGACAGATTTAGAACATGATAGGGTAGTCCTGCAGCTCAAGCA
 3000
 LeuLeuAsnGlyLeuGlyPheSerThrProAspGluLysPheGlnLysAspProProTyr
 ACTTCTAAATGGCCTAGGATTTTCTACCCAGATGACAAGTTCCAAAAAGACCCCTCCATA
 HisTrpMetGlyTyrGluLeuTrpProThrLysTrpLysLeuGlnLysIleGlnLeuPro
 CCACTGGATGGGCTATGAACATATGGCCAACTAAATGGAAGTTGCAGAAAAATACAGTTGCC
 3100
 GlnLysGluIleTrpThrValAsnAspIleGlnLysLeuValGlyValLeuAsnTrpAla
 CAAAAAGAAATATGCACAGTCAATGACATCCAGAAGCTAGTGGGTGTCCTAAATTGGGC

AlaGlnLeuTyrProGlyIleLysThrLysHisLeuCysArgLeuIleArgGlyLysMet
 AGCACAACCTCTACCCAGGGATAAAGACCAAACACTTATGTAGGTTAATCAGAGGAAAAAT
 3200
 ThrLeuThrGluGluValGlnTrpThrGluLeuAlaGluAlaGluLeuGluGluAsnArg
 CACACTCACAGAAGAAGTACAGTGGACAGAATTACAGAGAGCAGAGCTAGAAGAAAAACAG
 3300
 IleIleLeuSerGlnGluGlnGluGlyHisTyrTyrGlnGluGluLysGluLeuGluAla
 AATTATCCTAAGCCAGGAACAAGAGGGACACTATTACCAAGAAGAAAAAGAGCTAGAAGC
 ThrValGlnLysAspGlnGluAsnGlnTrpThrTyrLysIleHisGlnGluGluLysIle
 AACAGTCCAAAAGGATCAAGAGAATCAGTGGACATATAAAATACACCAGGAAGAAAAAT
 3400
 LeuLysValGlyLysTyrAlaLysValLysAsnThrHisThrAsnGlyIleArgLeuLeu
 TCTAAAAGTAGGAAAAATATGCAAAGGTGAAAAACACCCATACCAATGGAATCAGATTGTT
 AlaGlnValValGlnLysIleGlyLysGluAlaLeuValIleTrpGlyArgIleProLys
 AGCACAGGTAGTTTCAGAAAAATAGGAAAAAGAAGCACTAGTCATTTGGGGACGAATACCAA
 3500
 PheHisLeuProValGluArgGluIleTrpGluGlnTrpTrpAspAsnTyrTrpGlnVal
 ATTTACCTACCAGTAGAGAGAGAAATCTGGGAGCAGTGGTGGGATACTACTGGCAAGT
 3600
 ThrTrpIleProAspTrpAspPheValSerThrProProLeuValArgLeuAlaPheAsn
 GACATGGATCCCAGACTGGGACTTCTGTCTACCCACCACTGGTCAGGTTAGCGTTTAA
 LeuValGlyAspProIleProGlyAlaGluThrPheTyrThrAspGlySerCysAsnArg
 CCTGGTAGGGGATCCTATACAGGTGCAGAGACCTTCTACACAGATGGATCCTGCAATAG
 3700
 GlnSerLysGluGlyLysAlaGlyTyrValThrAspArgGlyLysAspLysValLysLys
 GCAATCAAAAGAAGGAAAAAGCAGGATATGTAACAGATAGAGGGAAAGACAAGGTAAAGAA
 LeuGluGlnThrThrAsnGlnGlnAlaGluLeuGluAlaPheAlaMetAlaLeuThrAsp
 ACTAGAGCAAACCTACCAATCAGCAAGCAGAACTAGAAGCCTTTCCGATGGCACTAACAGA
 3800
 SerGlyProLysValAsnIleIleValAspSerGlnTyrValMetGlyIleSerAlaSer
 CTCGGGTCCAAAAGTTAATATTATAGTAGACTCACAGTATGTAATGGGGATCAGTGCAAG
 3900
 GlnProThrGluSerGluSerLysIleValAsnGlnIleIleGluGluMetIleLysLys
 CCAACCAACAGAGTCAGAAAGTAAAAAGTGAACCAGATCATAGAAGAAATGATAAAAAA
 GluAlaIleTyrValAlaTrpValProAlaHisLysGlyIleGlyGlyAsnGlnGluVal
 GGAAGCAATCTATGTTGCATGGGTCCCAGCCCCACAAAGGCATAGGGGGAAACAGGAAGT
 4000
 AspHisLeuValSerGlnGlyIleArgGlnValLeuPheLeuGluLysIleGluProAla
 AGATCATTTAGTGAGTCAGGGTATCAGACAAGTGTTCCTGCAAAAAATAGAGCCCCC
 GlnGluGluHisGluLysTyrHisSerAsnValLysGluLeuSerHisLysPheGlyIle
 TCAGGAAGAACATGAAAAATATCATAGCAATGTAAAAGAACTGTCTCATAAATTTGGAAT
 4100
 ProAsnLeuValAlaArgGlnIleValAsnSerCysAlaGlnCysGlnGlnLysGlyGlu
 ACCCAATTTAGTGCCAAGGCAAAATAGTAAACTCATGTGCCCAATGTCAACAGAAAGGGGA
 4200
 AlaIleHisGlyGlnValAsnAlaGluLeuGlyThrTrpGlnMetAspCysThrHisLeu
 AGCTATACATGGGCAAGTAAATGCAGAACTAGGCACTTGGCAATGGACTGCACACATT

GluGlyLysIleIleIleValAlaValHisValAlaSerGlyPheIleGluAlaGluVal
 AGAAGCAAAGATCATTATAGTAGCAGTACATGTTGCAAGTGCATTTATAGAAGCAGAAGT
 4300
 IleProGlnGluSerGlyArgGlnThrAlaLeuPheLeuLeuLysLeuAlaSerArgTrp
 CATCGCACAGGAATCAGGAAGACAAACAGCACTCTTCCTATTGAAACTGCCAAGTAGGTG
 ProIleThrHisLeuHisThrAspAsnGlyAlaAsnPheThrSerGlnGluValLysMet
 GCCAATAACACACTTGCATACAGATAATGCTGCCAACTTCACTTCACAGGAGGTGAAGAT
 4400
 ValAlaTrpTrpIleGlyIleGluGlnSerPheGlyValProTyrAsnProGlnSerGln
 GGTAGCATGGTGGATAGGTATAGAACAATCCTTTGGAGTACCTTACAATCCACAGACCCA
 4500
 GlyValValGluAlaMetAsnHisHisLeuLysAsnGlnIleSerArgIleArgGluGln
 AGGAGTAGTAGAAGCAATGAATCACCATCTAAAAAACCAATAAGTAGAATCAGAGAACA
 AlaAsnThrIleGluThrIleValLeuMetAlaIleHisCysMetAsnPheLysArgArg
 GCCAAATACAATAGAAACAATAGTACTAATGCCAATTCATTGCATGAATTTTAAAAAGAAG
 4600
 GlyGlyIleGlyAspMetThrProSerGluArgLeuIleAsnMetIleThrThrGluGln
 GGGGGGAATAGGGGATATGACTCCATCAGAAAGATTAATCAATATGATCACCACAGAACA
 GluIleGlnPheLeuGlnAlaLysAsnSerLysLeuLysAspPheArgValTyrPheArg
 ACAGATACAATTCCTCCAAGCCAAAATTCAAATTTAAAGATTTTTCGGGTCTATTTTCAG
 4700
 GluGlyArgAspGlnLeuTrpLysGlyProGlyGluLeuLeuTrpLysGlyGluGlyAla
 AGAAGGCAGAGATCAGTTGTGGAAAGGACCTGGGGAACTACTGTGCAAAGGAGAAGCAGC
 4800
 ValLeuValLysValGlyThrAspIleLysIleIleProArgArgLysAlaLysIleIle
 AGTCCTAGTCAAGGTAGGAACAGACATAAAAAATAATACCAAGAAGGAAAGCCAAGATCAT
 ArgAspTyrGlyGlyArgGlnGluMetAspSerGlySerHisLeuGluGlyAlaArgGlu
 MetGluGluAspLysArgTrpIleValValProThrTrpArgValProGlyArg
 CAGAGACTATGGAGGAAGACAAGAGATGGATAGTGGTTCCACCTGGAGGGTGCCAGGGA
 4900
 AspGlyGluMetAla
 MetGluLysTrpHisSerLeuValLysTyrLeuLysTyrLysThrLysAspLeuGluLys
 GGATGGAGAAATGGCATAGCCTTGTCAAGTATCTAAAAATACAAAACAAAGGATCTAGAAA
 ValCysTyrValProHisHisLysValGlyTrpAlaTrpTrpThrCysSerArgValIle
 AGGTGTGCTATGTTCCCCACCATAAGGTGGGATGGGCATGGTGGACTTGCAGCAGCGTAA
 5000
 PheProLeuLysGlyAsnSerHisLeuGluIleGlnAlaTyrTrpAsnLeuThrProGlu
 TATTCCTATTAAAGGAACAGTCATCTAGAGATACAGGCATATTGGAACCTTAACACCAG
 5100
 LysGlyTrpLeuSerSerTyrSerValArgIleThrTrpTyrThrGluLysPheTrpThr
 AAAAAGGATGGCTCTCTCTTATTTCAGTAAGAATAACTTGGTACACAGAAAAGTTCTGGA
 AspValThrProAspCysAlaAspValLeuIleHisSerThrTyrPheProCysPheThr
 CAGATGTTACCCAGACTGTGCAGATGTCCTAATACATAGCACTTATTTCCCTTGCTTTA
 5200
 AlaGlyGluValArgArgAlaIleArgGlyGluLysLeuLeuSerCysCysAsnTyrPro
 CAGCAGGTGAAGTAAGAAGAGCCATCAGAGGGGAAAAGTTATTGTCCTGCTGCAATTATC
 ArgAlaHisArgAlaGlnValProSerLeuGlnPheLeuAlaLeuValValGlnGln
 CCCGAGCTCATAGAGCCAGGTACCGTCACTTCAATTTCTGGCCTTAGTGGTAGTGCAAC
 5300

MetThrAspProArgGluThrValProProGlyAsnSerGlyGluGluThrIleGly
 AsnAspArgProGlnArgAspSerThrThrArgLysGlnArgArgArgAspTyrArgArg
 AAAATGACAGACCCAGAGAGACAGTACCACCAGGAAACAGCGCGAAGAGACTATCGGA
 5400
 GluAlaPheAlaTrpLeuAsnArgThrValGluAlaIleAsnArgGluAlaValAsnHis
 GlyLeuArgLeuAlaLysGlnAspSerArgSerHisLysGlnArgSerSerGluSerPro
 GAGGCCTTCGCCTGGCTAAACAGGACAGTAGAAGCCATAAACAGAGAAGCAGTGAATCAC
 LeuProArgGluLeuIlePheGlnValTrpGlnArgSerTrpArgTyrTrpHisAspGlu
 ThrProArgThrTyrPheProGlyValAlaGluValLeuGluIleLeuAla
 CTACCCCGAGAACTTATTTTCCAGGTGTGGCAGAGGTCCTGGAGATACTGCCATGATGAA
 5500
 GlnGlyMetSerGluSerTyrThrLysTyrArgTyrLeuCysIleIleGlnLysAlaVal
 CAACGGATGTCAGAAAGTTACACAAAGTATAGATATTTGTGCATAATACAGAAAGCAGTG
 TyrMetHisValArgLysGlyCysThrCysLeuGlyArgGlyHisGlyProGlyGlyTrp
 TACATGCATGTTAGGAAAGGGTGTACTTGCTGGGGACGGGACATGGGCCAGGAGGGTGG
 5600
 ArgProGlyProProProProProProProGlyLeuVal
 MetAlaGluAlaProThrGlu
 AGACCAGGGCCTCCTCCTCCTCCCCCTCCAGGTCTGGTCTAATGGCTGAAGCACCAACAG
 5700
 LeuProProValAspGlyThrProLeuArgGluProGlyAspGluTrpIleIleGluIle
 AGCTCCCCCGGTGGATGGGACCCCACTGAGGGAGCCAGGGGATGAGTGGATAATAGAAA
 LeuArgGluIleLysGluGluAlaLeuLysHisPheAspProArgLeuLeuIleAlaLeu
 TCTTGACAGAAATAAAAGAAGAGCTTTAAAGCATTTTGACCCTCGCTTGCTAATTGCTC
 5800
 MetGluThrProLeuLysAlaProGluSerSerLeu
 GlyLysTyrIleTyrThrArgHisGlyAspThrLeuGluGlyAlaArgGluLeuIleLys
 TTGGCAAATATATCTATACTAGACATGGAGACACCCTTGAAGCGCCAGAGAGCTCATT
 LysSerCysAsnGluProPheSerArgThrSerGluGlnAspValAlaThrGlnGluLeu
 ValLeuGlnArgAlaLeuPheThrHisPheArgAlaGlyCysGlyHisSerArgIleGly
 AAGTCTTGCAACGAGCCCTTTTCACGCACTTCAGACCAGGATGTGGCCACTCAAGAATTG
 5900
 AlaArgGlnGlyGluGluIleLeuSerGlnLeuTyrArgProLeuGluThrCysAsnAsn
 GlnThrArgGlyGlyAsnProLeuSerAlaIleProThrProArgAsnMetGln
 GCCAGACAAGGGGAGGAAATCCTCTCTCAGCTATACCGACCCCTAGAAACATGCAATAAC
 6000
 SerCysTyrCysLysArgCysCysTyrHisCysGlnMetCysPheLeuAsnLysGlyLeu
 TCATGCTATTGTAAGCCATGCTGCTACCATTGTCAGATGTGTTTTCTAAACAAGGGGCTC
 GlyIleCysTyrGluArgLysGlyArgArgArgThrProLysLysThrLysThrHis
 MetAsnGluArgAlaAspGluGluGlyLeuGlnArgLysLeuArgLeuIle
 GGGATATGTTATGAACGAAAGGGCAGACGAAGAAGCACTCCAAAGAAACTAAGACTCAT
 6100
 ProSerProThrProAspLys
 ArgLeuLeuHisGlnThr
 MetMetAsnGlnLeuLeuIleAlaIleLeuLeuAla
 CCGTCTCCTACACCAGACAAGTGAGTATGATGAATCAGCTGCTTATTGCCATTTTATTAG
 SerAlaCysLeuValTyrCysThrGlnTyrValThrValPheTyrGlyValProThrTrp
 CTAGTGCTTGCTTAGTATATTGCACCCAATATGTAAGTGTGTTTTCTATGGCGTACCCACGT
 6200

LysAsnAlaThrIleProLeuPheCysAlaThrArgAsnArgAspThrTrpGlyThrIle
 GGAAAAATGCAACCATTCCTCTTTTGTGCAACCAGAAATAGGGATACTTGGGGAACCA
 6300
 GlnCysLeuProAspAsnAspAspTyrGlnGluIleThrLeuAsnValThrGluAlaPhe
 TACAGTGCCTTGCTGACAATGATGATTATCAGGAAATACTTTGAATGTAACAGAGCCTT
 AsnAlaTrpAsnAsnThrValThrGluGlnAlaIleGluAspValTrpHisLeuPheGlu
 TTGATGCATGCAATAATACAGTAACAGAACAAAGCAATAGAAGATGTCTGGCATCTATTCC
 6400
 ThrSerIleLysProCysValLysLeuThrProLeuCysValAlaMetLysCysSerSer
 AGACATCAATAAAACCATGTGTCAAACCTAACACCTTTATGTGTAGCAATGAAATGCCAGCA
 ThrGluSerSerThrGlyAsnAsnThrThrSerLysSerThrSerThrThrThrThr
 GCACAGAGAGCAGCAGCAGGGAACAACACAACCTCAAAGAGCACAAGCACAACCACAACCA
 6500
 ProThrAspGlnGluGlnGluIleSerGluAspThrProCysAlaArgAlaAspAsnCys
 CACCCACAGACCAGGAGCAAGAGATAAGTGAGGATACTCCATGCCGACGCGCAGACAACCT
 6600
 SerGlyLeuGlyGluGluGluThrIleAsnCysGlnPheAsnMetThrGlyLeuGluArg
 GCTCAGGATTGGGAGAGGAAGAAACGATCAATTGCCAGTTCAATATGACAGGATTAGAAA
 AspLysLysLysGlnTyrAsnGluThrTrpTyrSerLysAspValValCysGluThrAsn
 CAGATAAGAAAAACAGTATAATGAAACATGGTACTCAAAAGATGTGCTTTGTGAGACAA
 6700
 AsnSerThrAsnGlnThrGlnCysTyrMetAsnHisCysAsnThrSerValIleThrGlu
 ATAATAGCACAAATCAGACCCAGTGTACATGAACCATTGCAACACATCAGTCATCACAG
 SerCysAspLysHisTyrTrpAspAlaIleArgPheArgTyrCysAlaProProGlyTyr
 AATCATGTGACAAGCACTATTGGGATGCTATAAGGTTTAGATACTGTGCACCAACCGGCTT
 6800
 AlaLeuLeuArgCysAsnAspThrAsnTyrSerGlyPheAlaProAsnCysSerLysVal
 ATGCCCTATTAAAGATGTAATGATACCAATTATTACAGGCTTTGCACCAACTGTTCTAAAG
 6900
 ValAlaSerThrCysThrArgMetMetGluThrGlnThrSerThrTrpPheGlyPheAsn
 TAGTAGCTTCTACATGCACCAGGATGATGGAAACGCCAACTTCCACATGGTTTGGCTTTA
 GlyThrArgAlaGluAsnArgThrTyrIleTyrTrpHisGlyArgAspAsnArgThrIle
 ATGGCACTAGAGCAGAGAATAGAACATATATCTATTGGCATGGCAGAGATAATAGAACTA
 7000
 IleSerLeuAsnLysTyrTyrAsnLeuSerLeuHisCysLysArgProGlyAsnLysThr
 TCATCAGCTTAAACAAATATTATAATCTCAGTTTGCATTGTAAGAGGCCAGGCAATAAGA
 ValLysGlnIleMetLeuMetSerGlyHisValPheHisSerHisTyrGlnProIleAsn
 CAGTGAACAAATAATGCTTATGTCAGGACATGTGTTTCACTCCCACTACCAGCCGATCA
 7100
 LysArgProArgGlnAlaTrpCysTrpPheLysGlyLysTrpLysAspAlaMetGlnGlu
 ATAAAGACCCAGACAAGCATGGTGCTGGTTCAAAGGCCAAATGGAAAGACGCCATGCAGG
 7200
 ValLysGluThrLeuAlaLysHisProArgTyrArgGlyThrAsnAspThrArgAsnIle
 AGGTGAAGGAAACCTTGCAAAACATCCCAAGGTATAGAGGAACCAATGACACAAGGAATA
 SerPheAlaAlaProGlyLysGlySerAspProGluValAlaTyrMetTrpThrAsnCys
 TTAGCTTTGCAGCGCCAGGAAAAGGCTCAGACCCAGAAGTAGCATACATGTGGACTAACT
 7300
 ArgGlyGluPheLeuTyrCysAsnMetThrTrpPheLeuAsnTrpIleGluAsnLysThr
 GCAGAGGAGAGTTTCTCTACTGCAACATGACTTGGTTCTCAATTGGATAGAGAATAAGA

HisArgAsnTyrAlaProCysHisIleLysGlnIleIleAsnThrTrpHisLysValGly
CAGAGCGCAATTATGCACCGTGCCATATAAAGCAAATAATTAACACATGGCATAAGGTAG
7400

ArgAsnValTyrLeuProProArgGluGlyGluLeuSerCysAsnSerThrValThrSer
GCAGAAATGTATATTTGCCTCCACGGGAAGGGAGCTGCTCCTGCAACTCAACAGTAACCA
7500

IleIleAlaAsnIleAspTrpGlnAsnAsnAsnGlnThrAsnIleThrPheSerAlaGlu
GCATAATTGCTAACATTGACTGGCAAAACAATAATCAGACAAACATTACCTTTAGTGCAG

ValAlaGluLeuTyrArgLeuGluLeuGlyAspTyrLysLeuValGluIleThrProIle
AGGTGGCAGAACTATACAGATTGGAGTTGGGAGATTATAAATTGCTAGAAATAACACCAA
7600

GlyPheAlaProThrLysGluLysArgTyrSerSerAlaHisGlyArgHisThrArgGly
TTGGCTTCGCACCTACAAAAGAAAAAGATACTCCTCTGCTCACGGGAGACATACAAGAG

ValPheValLeuGlyPheLeuGlyPheLeuAlaThrAlaGlySerAlaMetGlyAlaAla
GTGTGTTTCGTGCTAGGGTTCTTGGGTTTTCTCGCAACAGCAGGTTCTGCAATGGGCGCGG
7700

SerLeuThrValSerAlaGlnSerArgThrLeuLeuAlaGlyIleValGlnGlnGlnGln
CGTCCCTGACCGTGTTCGGCTCAGTCCCGGACTTTACTGGCCGGGATACTGCAGCAACAGC
7800

GlnLeuLeuAspValValLysArgGlnGlnGluLeuLeuArgLeuThrValTrpGlyThr
AACAGCTGTTGCACGTGGTCAACAGACAACAAGAACTGTTGCGACTGACCGTCTGGGGAA

LysAsnLeuGlnAlaArgValThrAlaIleGluLysTyrLeuGlnAspGlnAlaArgLeu
CGAAAAACCTCCAGGCAACAGTCACTGCTATAGAGAAGTACCTACAGGACCAGGCCCGCGG
7900

AsnSerTrpGlyCysAlaPheArgGlnValCysHisThrThrValProTrpValAsnAsp
TAAATTCATGGGGATGTGCGTTTAGACAAGTCTGCCACACTACTGTACCATGGGTAAATG

SerLeuAlaProAspTrpAspAsnMetThrTrpGlnGluTrpGluLysGlnValArgTyr
ATTCCTTAGCACCTGACTGGGACAATATGACGTGGCAGGAATGGGAAAAACAAGTCCGCT
8000

LeuGluAlaAsnIleSerLysSerLeuGluGlnAlaGlnIleGlnGlnGluLysAsnMet
ACCTGGAGGCAAAATATCAGTAAAAGTTTAGAACAGGCACAAATTCAGCAAGAGAAAAATA
8100

TyrGluLeuGlnLysLeuAsnSerTrpAspIlePheGlyAsnTrpPheAspLeuThrSer
TGTATGAACTACAAAAATTAAATAGCTGGGATATTTTTGCCAATTGGTTTGACTTAACCT

TrpValLysTyrIleGlnTyrGlyValLeuIleIleValAlaValIleAlaLeuArgIle
CCTGGGTCAAGTATATTCAATATGGAGTGCTTATAATAGTAGCAGTAATAGCTTTAAGAA
8200

ValIleTyrValValGlnMetLeuSerArgLeuArgLysGlyTyrArgProValPheSer
TAGTGATATATGTAGTACAAATGTTAAGTAGGCTTAGAAAGGGCTATAGGCCTGTTTTCT

SerIleSerThrArgThrGlyAspSerGlnPro
AsnProTyrProGlnGlyProGlyThrAlaSerGln

SerProProGlyTyrIleGlnGlnIleHisIleHisLysAspArgGlyGlnProAlaAsn
CTTCCCCCCCCGGTTATATCCAACAGATCCATATCCACAAGGACCGGGCAGCCAGCCA
8300

ThrLysLysGlnLysLysThrValGluAlaThrValGluThrAspThrGlyProGlyArg
 ArgArgAsnArgArgArgArgTrpLysGlnArgTrpArgGlnIleLeuAlaLeuAlaAsp
 GlnGluThrGluGluAspGlyGlySerAsnGlyGlyAspArgTyrTrpProTrpProIle
 ACCAAGAAACAGAAGAAGACGGTCCAAGCAACGGTGGAGACAGATACTGGCCCTGGCCGA
 8400

SerIleTyrThrPheProAspProProAlaAspSerProLeuAspGlnThrIleGlnHis
 AlaTyrIleHisPheLeuIleArgGlnLeuIleArgLeuLeuThrArgLeuTyrSerIle
 TAGCATATATACATTTCTGATCCGCCAGCTGATTCCGCTCTTGACCAGACTATACAGCA

LeuGlnGlyLeuThrIleGlnGluLeuProAspProProThrHisLeuProGluSerGln
 CysArgAspLeuLeuSerArgSerPheLeuThrLeuGlnLeuIleTyrGlnAsnLeuArg
 TCTGCAGGGACTTACTATCCAGGAGCTTCTGACCCCTCCAACCTCATCTACCAGAATCTCA
 8500

ArgLeuAlaGluThr MetGlyAlaSerGlySerLysLys
 AspTrpLeuArgLeuArgThrAlaPheLeuGlnTyrGlyCysGluTrpIleGlnGluAla
 GAGACTGGCTGAGACTTAGAACAGCCTTCTTGCAATATGGGTGGAGTGGATCCAAGAAG
 HisSerArgProProArgGlyLeuGlnGluArgLeuLeuArgAlaArgAlaGlyAlaCys
 PheGlnAlaAlaAlaArgAlaThrArgGluThrLeuAlaGlyAlaCysArgGlyLeuTrp
 CATTCCAGGCCCGCCCGGAGGGCTACAAGAGAGACTCTTGCGGGCGCGTGCAGGGGCTTGT
 8600

GlyGlyTyrTrpAsnGluSerGlyGlyGluTyrSerArgPheGlnGluGlySerAspArg
 ArgValLeuGluArgIleGlyArgGlyIleLeuAlaValProArgArgIleArgGlnGly
 GCAGGGTATTGGAACGAATCGGGAGGGGAATACTCGCGGTCCAAGAAGGATCAGACAGG
 8700

GluGlnLysSerProSerCysGluGlyArgGlnTyrGlnGlnGlyAspPheMetAsnThr
 AlaGluIleAlaLeuLeu
 GAGCAGAAATCGCCCTCCTGTGAGGGACGGCAGTATCAGCAGGGAGACTTTATGAATACT

ProTrpLysAspProAlaAlaGluArgGluLysAsnLeuTyrArgGlnGlnAsnMetAsp
 CCATGGAAGGACCCAGCAGCAGAAAGGGAGAAAAATTTGTACAGGCAACAAAATATGGAT
 8800

AspValAspSerAspAspAspGlnValArgValSerValThrProLysValProLeu
 GATGTAGATTGAGATGATGATGACCAAGTAAGAGTTTCTGTACACCAAAAGTACCACTA

ArgProMetThrHisArgLeuAlaIleAspMetSerHisLeuIleLysThrArgGlyGly
 AGACCAATGACACATAGATTGGCAATAGATATGTCACATTTAATAAAAACAAGGGGGGGA
 8900

LeuGluGlyMetPheTyrSerGluArgArgHisLysIleLeuAsnIleTyrLeuGluLys
 CTGGAAGGGATGTTTTACAGTGAAAGAAGACATAAAATCTTAAATATATACTTAGAAAAG
 9000

GluGluGlyIleIleAlaAspTrpGlnAsnTyrThrHisGlyProGlyValArgTyrPro
 GAAGAAGGGATAATTGCAGATTGGCAGAACTACACTCATGGGCCAGGAGTAAGATACCCA

MetPhePheGlyTrpLeuTrpLysLeuValProValAspValProGlnGluGlyGluAsp
 ATGTTCTTTGGGTGGCTATGGAAGCTAGTACCAGTAGATGTCCCACAAGAAGGGGAGCAC
 9100

ThrGluThrHisCysLeuValHisProAlaGlnThrSerLysPheAspAspProHisGly
 ACTGAGACTCACTGCTTAGTACATCCAGCACAAACAAGCAAGTTTGATGACCCGCATGGG

GluThrLeuValTrpGluPheAspProLeuLeuAlaTyrSerTyrGluAlaPheIleArg
 GAGACACTAGTCTGGGAGTTTGATCCCTTGCTGGCTTATAGTTACGAGGCTTTTATTGCG
 9200

TyrProGluGluPheGlyHisLysSerGlyLeuProGluGluGluTrpLysAlaArgLeu
TACCCAGAGGAATTTGGGCACAAGTCAGGCCTGCCAGAGGAAGAGTGGAAGGCCAGACTG

9300

LysAlaArgGlyIleProPheSer

AAAGCAAGAGGAATACCATTTAGTTAAAGACAGGAACAGCTATACTTGGTCAGGGCAGGA

AGTAACTAACAGAAACAGCTGAGACTGCAGGGACTTTCCAGAAGGGGCTGTAACCAAGGG

9400

AGGGACATGGGAGGAGCTGGTGGGGAACGCCCTCATATTCTCTGTATAAATATACCCGCT

AGCTTGCAATTGTACTTCGGTCGCTCTGCGGAGAGGCTGGCAGATTGAGCCCTGGGAGGTT

9500

CTCTCCAGCAGTAGCAGGTAGAGCCTGGGTGTTCCCTGCTAGACTCTCACCAGCACTTGG

9600

CCGGTGCTGGGCAGACGGGCCACAGCTTGCTTGCTTAAAAACCTCCTTAATAAAGCTGCC

AGTTAGAAGCA

Example 5: Sequences of the Coding Regions
 for the Envelope Protein and GAG
 Product of the ROD HIV-2 Isolate

Through experimental analysis of the HIV-2 ROD isolate, the following sequences were identified for the regions encoding the env and gag gene products. One of ordinary skill in the art will recognize that the numbering for both gene regions which follow begins for convenience with "1" rather than the corresponding number for its initial nucleotide as given in Example 4, above, in the context of the complete genomic sequence.

Envelope sequence

MetMetAsnGlnLeuLeuIleAlaIleLeuLeuAlaSerAlaCys
 ATGATGAATCAGCTGCTTATTGCCATTTTATTAGCTAGTGCTTGC
 LeuValTyrCysThrGlnTyrValThrValPheTyrGlyValPro
 TTAGTATATTGCACCCAATATGTAACCTGTTTTCTATGGCGTACCC
 ThrTrpLysAsnAlaThrIleProLeuPheCysAlaThrArgAsn
 ACGTGGAAAAATGCAACCATTCCCCTSTTTTGTGCAACCAGAAAT
 100
 ArgAspThrTrpGlyThrIleGlnCysLeuProAspAsnAspAsp
 ACGGATACTTGGGGAAACCATACAGTGGCTTGGCTGACAATGATGAT
 TyrGlnGluIleThrLeuAsnValThrGluAlaPheAspAlaTrp
 TATCAGGAAATAACTTTGAATGTAACAGAGGCTTTTGATGCATGG
 200
 AsnAsnThrValThrGluGlnAlaIleGluAspValTrpHisLeu
 AATAATACAGTAACAGAACCAAGCAATAGAAGATGTCTGGCATCTA
 PheGluThrSerIleLysProCysValLysLeuThrProLeuCys
 TTCGAGACATCAATAAAACCATGTGTCAAACCTAACACCTTTATGT
 300
 ValAlaMetLysCysSerSerThrGluSerSerThrGlyAsnAsn
 GTAGCAATGAAATGACAGCAGCACAGAGAGCAGCAGCAGGGAACAAC
 ThrThrSerLysSerThrSerThrThrThrThrThrProThrAsp
 ACAACCTCAAAGAGCACAAGCACAACGACAACCACACCCAGAGAC
 400
 GlnGluGlnGluIleSerGluAspThrProCysAlaArgAlaAsp
 CAGGAGCAAGAGATAAGTGAGGATACTCCATGCCGACGGCGCAGAC
 AsnCysSerGlyLeuGlyGluGluGluThrIleAsnCysGlnPhe
 AACTGCTCAGGATTGGCAGAGGAAGAAACCATCAATTGCCAGTTC
 AsnMetThrGlyLeuGluArgAspLysLysLysGlnTyrAsnGlu
 AATATGACAGGATTAGAAAGAGATAAGAAAAAACACTATAATGAA
 500
 ThrTrpTyrSerLysAspValValCysGluThrAsnAsnSerThr
 ACATGGTACTCAAAAGATGTGGTTTGTGAGACAAATAATAGCACA
 AsnGlnThrGlnCysTyrMetAsnHisCysAsnThrSerValIle
 AATCAGACCCAGTGTTACATGAACCATTGCAACACATCAGTCATC
 600
 ThrGluSerCysAspLysHisTyrTrpAspAlaIleArgPheArg
 ACAGAAATCATGTGACAAGCACTATTGGGATGCTATAAGGTTTAGA
 TyrCysAlaProProGlyTyrAlaLeuLeuArgCysAsnAspThr
 TACTGTGCACCACCGGGTTATGCCCTATTAAGATGTAATGATACC
 700
 AsnTyrSerGlyPheAlaProAsnCysSerLysValValAlaSer
 AATTATTACAGGCTTTGCACCAACTGTTCTAAAGTAGTAGCTTCT

ThrCysThrArgMetMetGluThrGlnThrSerThrTrpPheGly
 ACATGCAGCAGGATGATGCAAACCCAACTTCCACATGGTTTGGC
 800
 PheAsnGlyThrArgAlaGluAsnArgThrTyrIleTyrTrpHis
 TTTAATGGCACTAGACGACAGAATAGAACATATATCTATTGGCAT
 GlyArgAspAsnArgThrIleIleSerLeuAsnLysTyrTyrAsn
 GGCAGAGATAATACAACATATCATCAGCTTAAACAAATATTATAAT
 900
 LeuSerLeuHisCysLysArgProGlyAsnLysThrValLysGln
 CTCAGTTTGCATTGTAAAGAGGCCAGGGAATAAGACAGTCAAACAA
 IleMetLeuMetSerGlyHisValPheHisSerHisTyrGlnPro
 ATAATGCTTATGTACAGGACATGTGTTTCACTGCCAGTACGAGCG
 IleAsnLysArgProArgGlnAlaTrpCysTrpPheLysGlyLys
 ATCAATAAAAGACCCAGACAAGCATGGTCTGCTGTTCAAAGGCCAAA
 1000
 TrpLysAspAlaMetGlnGluValLysThrLeuAlaLysHisPro
 TCGAAAGACGCCCATGACAGGAGGTGAAGAGCCTTGCAAAACATCCG
 ArgTyrArgGlyThrAsnAspThrArgAsnIleSerPheAlaAla
 AGGTATAGACGAACCAATGACACAAGCAATATTAGCTTTGCAGCG
 1100
 ProGlyLysGlySerAspProGluValAlaTyrMetTrpThrAsn
 CCAGGAAAAGGCTCAGACCCAGAAAGTAGCATACATGTGGACTAAC
 CysArgGlyGluPheLeuTyrCysAsnMetThrTrpPheLeuAsn
 TGCAGAGCAGAGTTTCTCTACTGCAACATGACTTGGTTCTCTCAAT
 1200
 TrpIleGluAsnLysThrHisArgAsnTyrAlaProCysHisIle
 TGGATAGAGAAATAAGACACACCCGCAATTATGCACCGTGCCATATA
 LysGlnIleIleAsnThrTrpHisLysValGlyArgAsnValTyr
 AAGCAAATAATTAACACATGGCATAAGGTAGGGAGAAATGTATAT
 1300
 LeuProProArgGluGlyGluLeuSerCysAsnSerThrValThr
 TTGCCTCCCAGGGAAGGGAGCTGCTCTGCAACTCAACAGTAACC
 SerIleIleAlaAsnIleAspTrpGlnAsnAsnAsnGlnThrAsn
 AGCATAATTGCTAACATTGACTGGCAAAACAATAATCAGACAAAC
 IleThrPheSerAlaGluValAlaGluLeuTyrArgLeuGluLeu
 ATTACCTTTAGTGCAGAGCTGGCAGAACTATACAGATTGGAGTTG
 1400
 GlyAspTyrLysLeuValGluIleThrProIleGlyPheAlaPro
 GGAGATTATAAATTGCTAGAAATAACACCAATTGGCTTCGCACCT

ThrLysGluLysArgTyrSerSerAlaHisGlyArgHisThrArg
ACAAAACAAAAAAGATACTCCTCTGCTCAGGGAGACATACAAGA

1500

GlyValPheValLeuGlyPheLeuGlyPheLeuAlaThrAlaGly
GGTGTGTTTCGTGCTAGGGTTCTTGGGTTTTCTCGCAACAGCAGGT

SerAlaMetGlyAlaArgAlaSerLeuThrValSerAlaGlnSer
TCTGCAATGGGCGCTCGACCGTCCCTGACCGTGTCTGGCTCAGTCC

1600

ArgThrLeuLeuAlaGlyIleValGlnGlnGlnGlnGlnLeuLeu
CGGACTTTACTGCGCGGGATAGTCCAGCAACAGCAACAGCTGTTG

AspValValLysArgGlnGlnGluLeuLeuArgLeuThrValTrp
GACGTGCTCAAGAGACAACAAGAACTGTTCCGACTGACCGTCTGG

1700

GlyThrLysAsnLeuGlnAlaArgValThrAlaIleGluLysTyr
GGAACGAAAAACCTCCAGGCAAGAGTCACTGCTATAGAGAAATAG

LeuGlnAspGlnAlaArgLeuAsnSerTrpGlyCysAlaPheArg
CTACAGGACCAGGCGCGCTAAATTCATCGGGATGTGCGTTTACA

1800

GlnValCysHisThrThrValProTrpValAsnAspSerLeuAla
CAAGTCTGCCACACTACTGTACCATGGGTTAATGATTCCCTTAGCA

ProAspTrpAspAsnMetThrTrpGlnGluTrpGluLysGlnVal
CCTGACTGGGACAATATGACGTGCGCAGGAATGGCAAAAAACAAGTC

ArgTyrLeuGluAlaAsnIleSerLysSerLeuGluGlnAlaGln
CGCTACCTGGAGGCAAAATATCACTAAAAAGTTTACAACAGGCACAA

1900

IleGlnGlnGluLysAsnMetTyrGluLeuGlnLysLeuAsnSer
ATTCAAGCAAGAGAAAAATATGTATGAACTACAAAAATTAAATAGC

TrpAspIlePheGlyAsnTrpPheAspLeuThrSerTrpValLys
TGGGATATTTTTGGCAATTGGTTTGACTTAACCTCCTCGGTCAAG

2000

TyrIleGlnTyrGlyValLeuIleIleValAlaValIleAlaLeu
TATATTCAATATCGAGTGCTTATAATAGTAGCAGTAATAGCTTTA

ArgIleValIleTyrValValGlnMetLeuSerArgLeuArgLys
AGAATAGTCATATATGTAGTACAAATGTTAAGTAGGCTTAGAAAG

2100

GlyTyrArgProValPheSerSerProProGlyTyrIleGln***
GGCTATAGCCCTGTTTTCTCTTCCCCCCCCGTTATATCCAATAG

IleHisIleHisLysAspArgGlyGlnProAlaAsnGluGluThr
 ATCCATATGCACAAGGACCGGGGACAGCCAGCCAACGAAGAAACA
 2200
 GluGluAspGlyGlySerAsnGlyGlyAspArgTyrTrpProTrp
 CAACAAGACGGTGCAGCAACGGTGCAGACAGATACTGCCCTCG
 ProIleAlaTyrIleHisPheLeuIleArgGlnLeuIleArgLeu
 GCGATAGCATATATACATTTCTGATCGGCCAGCTGATTGGCTC
 LeuThrArgLeuTyrSerIleCysArgAspLeuLeuSerArgSer
 TTCACCAGACTATACAGCATCTGCAGGCACTTACTATCCAGGAGC
 2300
 PheLeuThrLeuGlnLeuIleTyrGlnAsnLeuArgAspTrpLeu
 TTCCTGACCGCTCCAACCTCATCTACCAGAATCTCAGAGACTGGCTG
 ArgLeuArgThrAlaPheLeuGlnTyrGlyCysGluTrpIleGln
 AGACTTAGAACACGCTTCTTGCAATATCGGTGCCAGTGGATCCAA
 2400
 GluAlaPheGlnAlaAlaAlaArgAlaThrArgGluThrLeuAla
 GAAGCATTCAGCGCCCGCGAGGGCTACAACAGAGACTCTTGCG
 GlyAlaCysArgGlyLeuTrpArgValLeuGluArgIleGlyArg
 GCGCGCTGCAGGGGCTTGTTGGAGGCTATTGCAACGAATCGGGAGG
 2500
 GlyIleLeuAlaValProArgArgIleArgGlnGlyAlaGluIle
 GGAATACTCGCGCTTCCAAGAAGCATCAGACAGCGAGCAGAAAATC
 AlaLeuLeu***GlyThrAlaValSerAlaGlyArgLeuTyrGlu
 GCCCTCCTGTGAGGGACGGCAGTATCAGCAGGGAGACTTTATGAA
 2600
 TyrSerMetGluGlyProSerSerArgLysGlyGluLysPheVal
 TACTCCATGCAAGGACCCACCAGCAGAAAGGGAGAAAAATTTGTA
 GlnAlaThrLysTyrGly
 GAGGCAACAAAATATGGA

Gag sequence

MetGlyAlaArgAsnSerValLeuArgGlyLysLysAlaAspGlu
 ATGGGCGCGCAGAACTCCGTCTTGAGAGGGGAAAAAGCAGATCAA
 LeuGluArgIleArgLeuArgProGlyGlyLysLysLysTyrArg
 TTAGAAAGCAATCAGGTTACGGCCCCGGGAAAGAAAAAGTACAGG
 LeuLysHisIleValTrpAlaAlaAsnLysLeuAspArgPheGly
 CTAAGACATATTGCTGTGGCCAGCGAATAAATTGCACAGATTCCGA
 100
 LeuAlaGluSerLeuLeuGluSerLysGluGlyCysGlnLysIle
 TTAGCAGAGAGCCTGTTGGAGTCAAAAGACGGTTGTCAAAAAATT
 LeuThrValLeuAspProMetValProThrGlySerGluAsnLeu
 CTTACAGTTTTAGATCCAAATGCTACCGACAGGTTACAGAAAAATTA
 200
 LysSerLeuPheAsnThrValCysValIleTrpCysIleHisAla
 AAAAGTCTTTTTAATACTGCTGTGCGTCATTGCTGCATACAGCCA
 GluGluLysValLysAspThrGluGlyAlaLysGlnIleValArg
 GAAGAGAAAGTGAAAGATACTGAAGGAGCAAAACAAATAGTCCGG
 300
 ArgHisLeuValAlaGluThrGlyThrAlaGluLysMetProSer
 AGACATCTAGTGGCAGAAACAGGAAGTGCAGAGAAAAATGCCAAGC
 ThrSerArgProThrAlaProSerSerGluLysGlyGlyAsnTyr
 ACAAGTAGACCAACAGCACCATCTAGCGAGAAAGGAGGAAATTAC
 400
 ProValGlnHisValGlyGlyAsnTyrThrHisIleProLeuSer
 CCAGTCCAACATGTAGCGCGGCAACTACACCCATATACCGCTGAGT
 ProArgThrLeuAsnAlaTrpValLysLeuValGluGluLysLys
 CCGCGAACCCTAAATGCCTGGCTAAAATTACTAGAGGAAAAAAAG
 PheGlyAlaGluValValProGlyPheGlnAlaLeuSerGluGly
 TTCGGGGCAGAAAGTAGTGGCAGGATTTACAGGCAGTCTCAGAAAGGC
 500
 CysThrProTyrAspIleAsnGlnMetLeuAsnCysValGlyAsp
 TGCACGGCCCTATGATATCAACCAAAATGCTTAATTGTGTGGCGGAC
 HisGlnAlaAlaMetGlnIleIleArgGluIleIleAsnGluGlu
 CATCAAGCAGCCATGCCAGATAATCAGGAGAGATTATCAATGAGCAA
 600
 AlaAlaGluTrpAspValGlnHisProIleProGlyProLeuPro
 GCAGCAGAAATGGGATGTGCAACATCCAATACCAGGCCCTTAGCA
 AlaGlyGlnLeuArgGluProArgGlySerAspIleAlaGlyThr
 GCGGGGCAGCTTAGAGAGCCAAAGGGGATCTGACATAGCAGGCACA
 700
 ThrSerThrValGluGluGlnIleGlnTrpMetPheArgProGln
 ACAAGCACAGTAGAACAACAGATCCAGTGGATGTTTACGCCACAA

AsnProValProValGlyAsnIleTyrArgArgTrpIleGlnIle
 AATCCTGTACCAGTAGGAAACATCTATAGAAGATGGATCCAGATA
 800
 GlyLeuGlnLysCysValArgMetTyrAsnProThrAsnIleLeu
 GGATTGCAGAACTGTGTTCAGGATGTACAACCCGACCAACATCCTA
 AspIleLysGlnGlyProLysGluProPheGlnSerTyrValAsp
 GACATAAAACAGGCACCAAAGGAGCCGTTCCAAAGCTATGTAGAT
 900
 ArgPheTyrLysSerLeuArgAlaGluGlnThrAspProAlaVal
 AGATTCTACAAAAGCTTGAGGGCAGAACAAACAGATCCAGCAGTG
 LysAsnTrpMetThrGlnThrLeuLeuValGlnAsnAlaAsnPro
 AAGAATTGCGATGACCCAAACACTGCTAGTACAAAATGCCAACCCA
 AspCysLysLeuValLeuLysGlyLeuGlyMetAsnProThrLeu
 GACTGTAAATTACTGCTAAAAGGACTAGGCATGAACCCCTACCTTA
 1000
 GluGluMetLeuThrAlaCysGlnGlyValGlyGlyProGlyGln
 GAAGCAGATGCTGACCCGCTGTTCAGGCGCTAGGTCGCCCAGGCCAG
 LysAlaArgLeuMetAlaGluAlaLeuLysGluValIleGlyPro
 AAAGCTAGATTAATGGCAGAGGCCCTGAAAGAGGCTCATAGGACCT
 1100
 AlaProIleProPheAlaAlaAlaGlnGlnArgLysAlaPheLys
 GCCCCATATCCCATTCGCAGCAGGCCAGCAGACAAAGGCATTAAAA
 CysTrpAsnCysGlyLysGluGlyHisSerAlaArgGlnCysArg
 TGCTGGAACCTGTGGAAGCAAGGCCACTCGGCAAGACAATGCCCA
 1200
 AlaProArgArgGlnGlyCysTrpLysCysGlyLysProGlyHis
 GCACCTAGAAAGGCAGGGCTGCTGGAAGTGTGTAAGCCAGGACAC
 IleMetThrAsnCysProAspArgGlnAlaGlyPheLeuGlyLeu
 ATCATGACAAACTGCCCAGATAGACAGGCAGGTTTTTTTAGGACTG
 1300
 GlyProTrpGlyLysLysProArgAsnPheProValAlaGlnVal
 GCCCCTTGGGGAAGAAAGCCCCGCAACTTCCCCGTGGCCCAAGTT
 ProGlnGlyLeuThrProThrAlaProProValAspProAlaVal
 CCGCAGGGGCTGACACCAACAGCAGCCCCCAGTGGATCCAGCAGTG
 AspLeuLeuGluLysTyrMetGlnGlnGlyLysArgGlnArgGlu
 GATCTACTGGAGAAATATATGCAGCAAGGAAAAACAGAGAGAGAG
 1400
 GlnArgGluArgProTyrLysGluValThrGluAspLeuLeuHis
 CAGAGAGAGAGACCATAACAAGGAAGTGACAGAGGACTTACTGCAC
 LeuGluGlnGlyGluThrProTyrArgGlnProProThrGluAsp
 CTCGAGCAGGGGGAGACACCATACAGGGAGCCACCAACAGAGGAC
 1500
 LeuLeuHisLeuAsnSerLeuPheGlyLysAspGln
 TTGCTGCACCTCAATTCTCTTTTGGAAAAAGACCAAG

Example 6: Peptide Sequences Encoded By
 The ENV and GAG genes

The following coding regions for antigenic peptides, identified for convenience only by the nucleotide numbers of Example 5, within the env and gag gene regions are of particular interest.

env1 (1732-1809)

```

ArgValThrAlaIleGluLysTyr
AGAGTCACTGCTATAGAGAAATAG

LeuGlnAspGlnAlaArgLeuAsnSerTrpGlyCysAlaPheArg
CTACAGGACCAGGCGCGCTAAATTTCATGGGGATGTGCGTTTACA
1809

GlnValCys
CAAGTCTGC

```

env2 (1912-1983)

```

SerLysSerLeuGluGlnAlaGln
AGTAAAGTTTACAAACAGGCACAA

IleGlnGlnGluLysAsnMetTyrGluLeuGlnLysLeuAsnSer
ATTCAAGCAAGAGAAAAATATGTATGAACTACAAAAATTAAATAGC
1940

Trp
TGG

```

env3 (1482-1530)

```

Pro ThrLysGluLysArgTyrSerSerAlaHisGlyArgHisThrArg
CCT ACAAAGAAAAAAGATACTCCTCTGCTCACGGCAGACATACAAAG
1500

```

env4 (55-129)

```

CysThrGlnTyrValThrValPheTyrGlyValPro
TGCACCCCAATATGTAAGTGTITTTCTATGGCGTACCC

ThrTrpLysAsnAlaThrIleProLeuPheCysAlaThr
ACGTGCAAAAAATGCAACCATTCGCGTGTITTTGTGCAACC
100

```

env5 (175-231)

AspAsp
GATGAT

TyrGlnGlnIleThrLeuAsnValThrGlnAlaPheAspAlaTrp
TATCAGGAAATAACTTTGAAATGTAACAGAGGCTTTTCATGCATGG
200

AsnAsn
AATAAT

env6 (274-330)

GluThrSerIleLysProCysValLysLeuThrProLeuCys
GAGACATCAATAAAACCATGTGTGAAACTAACACCTTTATGT
300

ValAlaMetLysCys
GTAGCAATGAAATGC

env7 (607-660)

AsnHisCysAsnThrSerValIle
AACCATTGCAACACATCAGTCATC
610

ThrGluSerCysAspLysHisTyrTrpAsp
ACAGAAATCATGTGACAAGCACTATTGGGAT

env8 (661-720)

AlaIleArgPheArg
GCTATAAGGTTTAGA

TyrCysAlaProProGlyTyrAlaLeuLeuArgCysAsnAspThr
TACTGTGCACCACCGGGTTATGCCCTATTAAAGATGTAATCATACC
700

env9 (997-1044)

LysArgProArgGlnAlaTrpCysTrpPheLysGlyLys
AAAAGACCCAGACAAGCATGGTGGTTCAAAAGCCAAA
1000

TrpLysAsp
TGGAAAGAC

env10 (1132-1215)

LysGlySerAspProGluValAlaTyrMetTrpThrAsn
AAAGGCTCAGACCCAGAACTAGCATACATGTGGACTAAC
CysArgGlyGluPheLeuTyrCysAsnMetThrTrpPheLeuAsn
TGCAGAGGAGAGTTTCTCTACTGCAACATGACTTGGTTCTCAAT
1200

env11 (1237-1305)

ArgAsnTyrAlaProCysHisIle
CGCAATTATGCACCGTGCCATATA
LysGlnIleIleAsnThrTrpHisLysValGlyArgAsnValTyr
AAGCAAATAATTAACACATGGCATAAGCTAGGAGAAATGTATAT
1300

gag1 (991-1053)

AspCysLysLeuValLeuLysGlyLeuGlyMetAsnProThrLeu
GACTGTAAATTACTGCTAAAAGGACTAGGGATGAACCCCTACCTTA
1000
GluGluMetLeuThrAla
GAAGAGATGCTGACCGCC

Of the foregoing peptides, env1, env2, env3 and gag1 are particularly contemplated for diagnostic purposes, and env4, env5, env6, env7, env8, env9, env10 and env11 are particularly contemplated as protecting agents. These peptides have been selected in part because of their sequence homology to certain of the envelope and gag protein products of other of the retroviruses in the HIV group. For vaccinating purposes, the foregoing peptides may be coupled to a carrier protein by utilizing

suitable and well known techniques to enhance the host's immune response. Adjuvants such as calcium phosphate or alum hydroxide may also be added. The foregoing peptides can be synthesized by conventional protein synthesis techniques, such as that of Merrifield.

It will be apparent to those skilled in the art that various modifications and variations can be made in the processes and products of the present invention. Thus, it is intended that the present application cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents. For convenience in interpreting the following claims, the following table sets forth the correspondence between codon codes and amino acids and the correspondence between three-letter and one-letter amino acid symbols.

DNA CODON				AMINO ACID 3 LET.				AMINO ACID 1 LET.			
:	:	12:	T C A G	:	T C A G	:	T C A G	:	T C A G	:	:
:	1 :	3\:	:	:	:	:	:	:	:	:	:
:	:	T :	TTT TCT TAT TGT	:	PHE SER TYR CYS	:	F S Y C	:	:	:	:
:	T :	C :	TTC TCC TAC TGC	:	PHE SER TYR CYS	:	F S Y C	:	:	:	:
:	:	A :	TTA TCA TAA TGA	:	LEU SER *** **	:	L S * *	:	:	:	:
:	:	G :	TTG TCG TAG TGG	:	LEU SER *** TRP	:	L S * W	:	:	:	:
:	:	T :	CTT CCT CAT CGT	:	LEU PRO HIS ARG	:	L P H R	:	:	:	:
:	C :	C :	CTC CCC CAC CGC	:	LEU PRO HIS ARG	:	L P H R	:	:	:	:
:	:	A :	CTA CCA CAA CGA	:	LEU PRO GLN ARG	:	L P Q R	:	:	:	:
:	:	G :	CTG CCG CAG CGG	:	LEU PRO GLN ARG	:	L P Q R	:	:	:	:
:	:	T :	ATT ACT AAT AGT	:	ILE THR ASN SER	:	I T N S	:	:	:	:
:	A :	C :	ATC ACC AAC AGC	:	ILE THR ASN SER	:	I T N S	:	:	:	:
:	:	A :	ATA ACA AAA AGA	:	ILE THR LYS ARG	:	I T K R	:	:	:	:
:	:	G :	ATG ACG AAG AGG	:	MET THR LYS ARG	:	M T K R	:	:	:	:
:	:	T :	GTT GCT GAT GGT	:	VAL ALA ASP GLY	:	V A D G	:	:	:	:
:	G :	C :	GTC GCC GAC GGC	:	VAL ALA ASP GLY	:	V A D G	:	:	:	:
:	:	A :	GTA GCA GAA GGA	:	VAL ALA GLU GLY	:	V A E G	:	:	:	:
:	:	G :	GTG GCG GAG GGG	:	VAL ALA GLU GLY	:	V A E G	:	:	:	:

3 Letter

1 Letter

CODONS

ALA	A	GCT GCC GCA GCG
ARG	R	CGT CGC CGA CGG AGA AGG
ASN	N	AAT AAC
ASP	D	GAT GAC
CYS	C	TGT TGC
GLN	Q	CAA CAG
GLU	E	GAA GAG
GLY	G	GGT GGC GGA GGG
HIS	H	CAT CAC
ILE	I	ATT ATC ATA
LEU	L	CTT CTC CTA CTG TTA TTG
LYS	K	AAA AAG
MET	M	ATG
PHE	F	TTT TTC
PRO	P	CCT CCC CCA CCG
SER	S	TCT TCC TCA TCG AGT AGC
THR	T	ACT ACC ACA ACG
TRP	W	TGG
TYR	Y	TAT TAC
VAL	V	GTT GTC GTA GTG
***	*	TAA TAG TGA